253 related articles for article (PubMed ID: 10410767)
1. Use of apomorphine in clinical practice.
MacMahon DG
Adv Neurol; 1999; 80():529-33. PubMed ID: 10410767
[No Abstract] [Full Text] [Related]
2. Apomorphine-induced eosinophilic panniculitis and hypereosinophilia in Parkinson disease.
Pot C; Oppliger R; Castillo V; Coeytaux A; Hauser C; Burkhard PR
Neurology; 2005 Jan; 64(2):392-3. PubMed ID: 15668455
[No Abstract] [Full Text] [Related]
3. Use of apomorphine in Parkinson's disease.
Stocchi F
Neurol Sci; 2008 Dec; 29 Suppl 5():S383-6. PubMed ID: 19381769
[TBL] [Abstract][Full Text] [Related]
4. The pragmatic use of apomorphine at the end of life.
Dewhurst F; Lee M; Wood B
Palliat Med; 2009 Dec; 23(8):777-9. PubMed ID: 19837701
[TBL] [Abstract][Full Text] [Related]
5. New treatment for people with Parkinson's.
FDA Consum; 2004; 38(4):5. PubMed ID: 15346564
[No Abstract] [Full Text] [Related]
6. Movement characteristics in Parkinson's disease: determination of dopaminergic responsiveness and threshold.
van Hilten JJ; Wagemans EA; Ghafoerkhan SF; van Laar T
Clin Neuropharmacol; 1997 Oct; 20(5):402-8. PubMed ID: 9331516
[TBL] [Abstract][Full Text] [Related]
7. Apomorphine therapy in Parkinson's disease: a review.
Haq IU; Lewitt PA; Fernandez HH
Expert Opin Pharmacother; 2007 Nov; 8(16):2799-809. PubMed ID: 17956200
[TBL] [Abstract][Full Text] [Related]
8. DA agonists -- non-ergot derivatives: apomorphine: management of Parkinson's disease.
Mov Disord; 2002; 17 Suppl 4():S83-9. PubMed ID: 12211146
[No Abstract] [Full Text] [Related]
9. [Candidate patient for subcutaneous apomorphine injection].
Chacón JR; Mata M
Rev Neurol; 2012; 55 Suppl 1():S7-9. PubMed ID: 23169232
[TBL] [Abstract][Full Text] [Related]
10. [Apomorphine for treatment of "off-periods" in Parkinson's disease].
Zoldan J; Merims D; Kuritzky A; Ziv I; Melamed E
Harefuah; 1999 Nov; 137(10):444-6, 512, 511. PubMed ID: 10959339
[TBL] [Abstract][Full Text] [Related]
11. [Subcutaneous continuous apomorphine infusion: treatment initiation and follow up].
Grandas FJ; Sesar-Ignacio Á
Rev Neurol; 2012; 55 Suppl 1():S21-4. PubMed ID: 23169229
[TBL] [Abstract][Full Text] [Related]
12. [Candidate patient for treatment with continuous apomorphine infusion].
Martí MJ; Kulisevsky J
Rev Neurol; 2012; 55 Suppl 1():S15-9. PubMed ID: 23169228
[TBL] [Abstract][Full Text] [Related]
13. Practical considerations in the use of apomorphine injectable.
Bowron A
Neurology; 2004 Mar; 62(6 Suppl 4):S32-6. PubMed ID: 15037670
[TBL] [Abstract][Full Text] [Related]
14. Blood pressure effects of apomorphine and domperidone in parkinsonism.
Pollak P; Mallaret M; Gaio JM; Hommel M; Perret J
Adv Neurol; 1987; 45():263-6. PubMed ID: 3548261
[No Abstract] [Full Text] [Related]
15. Future delivery systems for apomorphine in patients with Parkinson's disease.
van Laar T; Van der Geest R; Danhof M
Adv Neurol; 1999; 80():535-44. PubMed ID: 10410768
[No Abstract] [Full Text] [Related]
16. 10 questions about using apomorphine for Parkinson disease.
Dewey RB
Neurologist; 2005 May; 11(3):190-2. PubMed ID: 15860144
[No Abstract] [Full Text] [Related]
17. Medical hazards of the internet: gambling in Parkinson's disease.
Larner AJ
Mov Disord; 2006 Oct; 21(10):1789. PubMed ID: 16941457
[No Abstract] [Full Text] [Related]
18. Parkinson's disease.
Clarke C; Moore AP
Clin Evid; 2002 Jun; (7):1208-20. PubMed ID: 12230738
[No Abstract] [Full Text] [Related]
19. Parkinson's disease.
Clarke C; Moore A
Clin Evid; 2002 Dec; (8):1370-85. PubMed ID: 12603943
[No Abstract] [Full Text] [Related]
20. [Presentation].
García-Ruiz PJ; Luquin MR; Martínez-Castrillo JC
Rev Neurol; 2012; 55 Suppl 1():S1. PubMed ID: 23169226
[No Abstract] [Full Text] [Related]
[Next] [New Search]
